Thermo Fisher Scientific (TMO) Stock Forecast, Price Target & Predictions
TMO Stock Forecast
Thermo Fisher Scientific stock forecast is as follows: an average price target of $646.32 (represents a 5.87% upside from TMO’s last price of $610.49) and a rating consensus of 'Buy', based on 16 wall street analysts offering a 1-year stock forecast.
TMO Price Target
The average price target for Thermo Fisher Scientific (TMO) is $646.32 based on 1-year price targets from 16 Wall Street analysts in the past 3 months, with a price target range of $711.00 to $505.00. This represents a potential 5.87% upside from TMO's last price of $610.49.
TMO Analyst Ratings
According to 16 Wall Street analysts, Thermo Fisher Scientific's rating consensus is 'Buy'. The analyst rating breakdown for TMO stock is 0 'Strong Buy' (0.00%), 13 'Buy' (81.25%), 3 'Hold' (18.75%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Thermo Fisher Scientific Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 16, 2024 | Derik de Bruin | Bank of America Securities | $675.00 | $611.17 | 10.44% | 10.57% |
| Jul 25, 2024 | Andrew Cooper | Raymond James | $660.00 | $593.86 | 11.14% | 8.11% |
| Jun 28, 2024 | Luke Sergott | Barclays | $600.00 | $550.78 | 8.94% | -1.72% |
| Apr 30, 2024 | Sidharth Sahoo | HSBC | $670.00 | $576.89 | 16.14% | 9.75% |
| Apr 25, 2024 | Justin Bowers | Deutsche Bank | $610.00 | $577.39 | 5.65% | -0.08% |
| Apr 25, 2024 | Luke Sergott | Barclays | $615.00 | $577.39 | 6.51% | 0.74% |
| Dec 28, 2023 | Catherine Schulte | Robert W. Baird | $670.00 | $531.65 | 26.02% | 9.75% |
| Oct 26, 2023 | Andrew Cooper | Raymond James | $530.00 | $444.45 | 19.25% | -13.18% |
| Jul 13, 2023 | Thermo Fisher | Credit Suisse | $620.00 | $525.63 | 17.95% | 1.56% |
| Feb 02, 2023 | - | Cowen & Co. | $711.00 | $591.95 | 20.11% | 16.46% |
The latest Thermo Fisher Scientific stock forecast, released on Sep 16, 2024 by Derik de Bruin from Bank of America Securities, set a price target of $675.00, which represents a 10.44% increase from the stock price at the time of the forecast ($611.17), and a 10.57% increase from TMO last price ($610.49).
Thermo Fisher Scientific Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 3 | 8 |
| Avg Price Target | $675.00 | $645.00 | $628.75 |
| Last Closing Price | $610.49 | $610.49 | $610.49 |
| Upside/Downside | 10.57% | 5.65% | 2.99% |
In the current month, the average price target of Thermo Fisher Scientific stock is $675.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 10.57% increase as opposed to Thermo Fisher Scientific's last price of $610.49. This month's average price target is up 4.65% compared to last quarter, and up 7.36% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 16, 2024 | Bank of America Securities | Buy | Buy | Hold |
| Aug 27, 2024 | Wells Fargo | Underweight | Overweight | Initialise |
| Jul 25, 2024 | Raymond James | Outperform | Outperform | Hold |
| Jul 25, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Jul 24, 2024 | Goldman Sachs | Buy | Buy | Hold |
| Jun 28, 2024 | Barclays | Equal-Weight | Equal-Weight | Hold |
| Jun 03, 2024 | Jefferies | - | Buy | Upgrade |
| Apr 25, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Apr 25, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Apr 25, 2024 | Deutsche Bank | Buy | Buy | Hold |
Thermo Fisher Scientific's last stock rating was published by Bank of America Securities on Sep 16, 2024. The company gave TMO a "Buy" rating, the same as its previous rate.
Thermo Fisher Scientific Financial Forecast
Thermo Fisher Scientific Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $10.89B | $10.57B | $10.69B | $10.71B | $11.45B | $10.68B | $10.97B | $11.82B | $10.70B | $9.33B | $9.27B | $9.91B | $10.55B | $8.52B | $6.92B | $6.23B | $6.83B | $6.27B |
| Avg Forecast | $13.03B | $12.12B | $11.90B | $11.59B | $12.09B | $11.31B | $11.19B | $10.89B | $11.35B | $10.64B | $10.50B | $10.15B | $10.73B | $10.60B | $10.99B | $10.65B | $10.43B | $9.94B | $9.97B | $10.69B | $8.71B | $8.38B | $8.73B | $9.72B | $9.58B | $7.65B | $6.10B | $6.17B | $6.78B | $6.18B |
| High Forecast | $13.13B | $12.21B | $11.99B | $11.68B | $12.18B | $11.40B | $11.28B | $10.97B | $11.43B | $10.71B | $10.58B | $10.23B | $10.77B | $10.75B | $11.07B | $10.73B | $10.50B | $10.02B | $9.97B | $10.90B | $8.88B | $8.54B | $8.90B | $9.90B | $9.76B | $7.80B | $6.22B | $6.28B | $6.91B | $6.30B |
| Low Forecast | $12.83B | $11.92B | $11.71B | $11.41B | $11.89B | $11.13B | $11.02B | $10.72B | $11.17B | $10.59B | $10.34B | $9.99B | $10.70B | $10.39B | $10.81B | $10.48B | $10.26B | $9.79B | $9.97B | $10.53B | $8.58B | $8.25B | $8.60B | $9.57B | $9.43B | $7.53B | $6.01B | $6.07B | $6.68B | $6.09B |
| # Analysts | 6 | 12 | 11 | 10 | 9 | 8 | 7 | 6 | 7 | 13 | 6 | 4 | 9 | 18 | 14 | 9 | 9 | 15 | 8 | 11 | 9 | 9 | 14 | 4 | 6 | 4 | 6 | 4 | 5 | 3 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.01% | 1.00% | 0.97% | 1.01% | 1.10% | 1.07% | 1.10% | 1.11% | 1.23% | 1.11% | 1.06% | 1.02% | 1.10% | 1.11% | 1.13% | 1.01% | 1.01% | 1.01% |
Thermo Fisher Scientific's average Quarter revenue forecast for Mar 24 based on 4 analysts is $10.15B, with a low forecast of $9.99B, and a high forecast of $10.23B. TMO's average Quarter revenue forecast represents a -6.72% decrease compared to the company's last Quarter revenue of $10.89B (Dec 23).
Thermo Fisher Scientific EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 12 | 11 | 10 | 9 | 8 | 7 | 6 | 7 | 13 | 6 | 4 | 9 | 18 | 14 | 9 | 9 | 15 | 8 | 11 | 9 | 9 | 14 | 4 | 6 | 4 | 6 | 4 | 5 | 3 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $1.85B | $3.06B | $2.79B | $2.63B | $2.95B | $2.65B | $2.92B | $3.54B | $2.71B | $2.93B | $2.83B | $3.50B | $3.64B | $2.97B | $1.96B | $1.53B | $1.76B | $1.56B |
| Avg Forecast | $3.66B | $3.40B | $3.34B | $3.26B | $3.39B | $3.18B | $3.14B | $3.06B | $3.19B | $2.99B | $2.95B | $2.56B | $3.01B | $2.98B | $3.09B | $2.32B | $2.93B | $2.27B | $2.80B | $1.84B | $2.05B | $2.35B | $2.45B | $2.73B | $3.35B | $2.06B | $1.69B | $1.45B | $1.75B | $1.50B |
| High Forecast | $3.69B | $3.43B | $3.37B | $3.28B | $3.42B | $3.20B | $3.17B | $3.08B | $3.21B | $3.01B | $2.97B | $3.07B | $3.03B | $3.02B | $3.11B | $2.79B | $2.95B | $2.72B | $2.80B | $2.20B | $2.46B | $2.40B | $2.50B | $2.78B | $4.02B | $2.47B | $2.03B | $1.74B | $2.10B | $1.79B |
| Low Forecast | $3.60B | $3.35B | $3.29B | $3.20B | $3.34B | $3.13B | $3.09B | $3.01B | $3.14B | $2.97B | $2.90B | $2.04B | $3.01B | $2.92B | $3.04B | $1.86B | $2.88B | $1.81B | $2.80B | $1.47B | $1.64B | $2.32B | $2.41B | $2.69B | $2.68B | $1.65B | $1.36B | $1.16B | $1.40B | $1.20B |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.62% | 1.03% | 0.91% | 1.13% | 1.01% | 1.17% | 1.04% | 1.93% | 1.32% | 1.24% | 1.15% | 1.28% | 1.09% | 1.44% | 1.16% | 1.05% | 1.00% | 1.04% |
4 analysts predict TMO's average Quarter EBITDA for Mar 24 to be $2.56B, with a high of $3.07B and a low of $2.04B. This is 37.82% upper than Thermo Fisher Scientific's previous annual EBITDA (Dec 23) of $1.85B.
Thermo Fisher Scientific Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 12 | 11 | 10 | 9 | 8 | 7 | 6 | 7 | 13 | 6 | 4 | 9 | 18 | 14 | 9 | 9 | 15 | 8 | 11 | 9 | 9 | 14 | 4 | 6 | 4 | 6 | 4 | 5 | 3 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $1.63B | $1.72B | $1.36B | $1.29B | $1.58B | $1.50B | $1.66B | $2.21B | $1.67B | $1.90B | $1.83B | $2.34B | $2.50B | $1.93B | $1.16B | $788.00M | $1.00B | $760.00M |
| Avg Forecast | $2.84B | $2.49B | $2.41B | $2.28B | $2.55B | $2.27B | $2.21B | $2.12B | $2.30B | $2.01B | $1.96B | $1.32B | $2.16B | $2.15B | $2.08B | $1.20B | $1.99B | $1.48B | $1.92B | $946.98M | $1.26B | $1.82B | $2.12B | $2.58B | $2.30B | $1.34B | $997.13M | $748.60M | $999.17M | $741.46M |
| High Forecast | $2.87B | $2.52B | $2.43B | $2.31B | $2.57B | $2.29B | $2.23B | $2.14B | $2.32B | $2.07B | $1.98B | $1.58B | $2.20B | $2.21B | $2.10B | $1.44B | $2.01B | $1.77B | $1.92B | $1.14B | $1.51B | $1.86B | $2.18B | $2.65B | $2.76B | $1.61B | $1.20B | $898.32M | $1.20B | $889.76M |
| Low Forecast | $2.79B | $2.44B | $2.36B | $2.24B | $2.49B | $2.22B | $2.16B | $2.08B | $2.25B | $1.99B | $1.92B | $1.05B | $2.15B | $2.08B | $2.03B | $958.34M | $1.95B | $1.18B | $1.92B | $757.58M | $1.01B | $1.78B | $2.08B | $2.53B | $1.84B | $1.07B | $797.71M | $598.88M | $799.34M | $593.17M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.75% | 0.80% | 0.66% | 1.08% | 0.79% | 1.01% | 0.87% | 2.34% | 1.32% | 1.05% | 0.86% | 0.90% | 1.09% | 1.44% | 1.16% | 1.05% | 1.00% | 1.03% |
Thermo Fisher Scientific's average Quarter net income forecast for Mar 24 is $1.32B, with a range of $1.05B to $1.58B. TMO's average Quarter net income forecast represents a -19.16% decrease compared to the company's last Quarter net income of $1.63B (Dec 23).
Thermo Fisher Scientific SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 12 | 11 | 10 | 9 | 8 | 7 | 6 | 7 | 13 | 6 | 4 | 9 | 18 | 14 | 9 | 9 | 15 | 8 | 11 | 9 | 9 | 14 | 4 | 6 | 4 | 6 | 4 | 5 | 3 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $1.67B | $1.58B | $1.67B | $1.65B | $1.84B | $1.74B | $1.74B | $1.81B | $2.28B | $2.00B | $1.90B | $1.83B | $2.08B | $1.59B | $1.71B | $1.55B | $1.51B | $1.54B |
| Avg Forecast | $2.24B | $2.08B | $2.04B | $1.99B | $2.07B | $1.94B | $1.92B | $1.87B | $1.95B | $1.83B | $1.80B | $2.59B | $1.84B | $1.82B | $1.89B | $2.36B | $1.79B | $1.21B | $1.71B | $1.86B | $1.73B | $1.44B | $1.50B | $1.67B | $1.91B | $1.10B | $1.48B | $1.47B | $1.51B | $1.50B |
| High Forecast | $2.25B | $2.10B | $2.06B | $2.00B | $2.09B | $1.96B | $1.94B | $1.88B | $1.96B | $1.84B | $1.82B | $3.11B | $1.85B | $1.85B | $1.90B | $2.83B | $1.80B | $1.46B | $1.71B | $2.24B | $2.07B | $1.47B | $1.53B | $1.70B | $2.29B | $1.33B | $1.77B | $1.77B | $1.81B | $1.80B |
| Low Forecast | $2.20B | $2.05B | $2.01B | $1.96B | $2.04B | $1.91B | $1.89B | $1.84B | $1.92B | $1.82B | $1.77B | $2.07B | $1.84B | $1.78B | $1.86B | $1.89B | $1.76B | $971.90M | $1.71B | $1.49B | $1.38B | $1.42B | $1.48B | $1.64B | $1.53B | $883.54M | $1.18B | $1.18B | $1.21B | $1.20B |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.91% | 0.87% | 0.89% | 0.70% | 1.03% | 1.43% | 1.02% | 0.97% | 1.32% | 1.39% | 1.27% | 1.09% | 1.09% | 1.44% | 1.16% | 1.05% | 1.00% | 1.03% |
Thermo Fisher Scientific's average Quarter SG&A projection for Mar 24 is $2.59B, based on 4 Wall Street analysts, with a range of $2.07B to $3.11B. The forecast indicates a 55.12% rise compared to TMO last annual SG&A of $1.67B (Dec 23).
Thermo Fisher Scientific EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 12 | 11 | 10 | 9 | 8 | 7 | 6 | 7 | 13 | 6 | 4 | 9 | 18 | 14 | 9 | 9 | 15 | 8 | 11 | 9 | 9 | 14 | 4 | 6 | 4 | 6 | 4 | 5 | 3 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $4.21 | $4.44 | $3.53 | $3.34 | $4.03 | $3.82 | $4.25 | $5.66 | $4.23 | $4.83 | $4.65 | $5.93 | $6.30 | $4.88 | $2.92 | $1.99 | $2.51 | $1.89 |
| Avg Forecast | $7.43 | $6.51 | $6.28 | $5.96 | $6.65 | $5.92 | $5.77 | $5.54 | $5.99 | $5.25 | $5.12 | $4.71 | $5.64 | $5.61 | $5.42 | $5.03 | $5.20 | $4.83 | $4.99 | $6.22 | $4.93 | $4.68 | $5.47 | $6.66 | $6.56 | $4.33 | $2.89 | $2.80 | $3.54 | $2.87 |
| High Forecast | $7.50 | $6.57 | $6.35 | $6.02 | $6.71 | $5.97 | $5.83 | $5.60 | $6.05 | $5.41 | $5.17 | $4.76 | $5.73 | $5.76 | $5.48 | $5.08 | $5.25 | $4.88 | $4.99 | $6.37 | $5.05 | $4.80 | $5.61 | $6.82 | $6.73 | $4.44 | $2.96 | $2.87 | $3.63 | $2.94 |
| Low Forecast | $7.27 | $6.37 | $6.15 | $5.84 | $6.51 | $5.79 | $5.65 | $5.43 | $5.87 | $5.18 | $5.02 | $4.61 | $5.62 | $5.43 | $5.31 | $4.92 | $5.09 | $4.73 | $4.99 | $6.10 | $4.83 | $4.59 | $5.36 | $6.53 | $6.43 | $4.25 | $2.83 | $2.74 | $3.47 | $2.81 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.75% | 0.79% | 0.65% | 0.66% | 0.78% | 0.79% | 0.85% | 0.91% | 0.86% | 1.03% | 0.85% | 0.89% | 0.96% | 1.13% | 1.01% | 0.71% | 0.71% | 0.66% |
According to 4 Wall Street analysts, Thermo Fisher Scientific's projected average Quarter EPS for Mar 24 is $4.71, with a low estimate of $4.61 and a high estimate of $4.76. This represents a 11.85% increase compared to TMO previous annual EPS of $4.21 (Dec 23).
Thermo Fisher Scientific Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| GH | Guardant Health | $25.09 | $57.27 | 128.26% | Buy |
| ILMN | Illumina | $130.21 | $200.82 | 54.23% | Buy |
| CRL | Charles River Laboratories | $206.21 | $316.29 | 53.38% | Buy |
| DHR | Danaher | $272.47 | $313.59 | 15.09% | Buy |
| TMO | Thermo Fisher Scientific | $610.49 | $646.32 | 5.87% | Buy |
| A | Agilent | $138.35 | $144.90 | 4.73% | Buy |
| RVTY | Revvity | $122.71 | $123.83 | 0.91% | Hold |
| WAT | Waters | $328.97 | $325.00 | -1.21% | Buy |
| MTD | Mettler-Toledo | $1.38K | $1.36K | -1.38% | Hold |
| IDXX | IDEXX Laboratories | $512.27 | $479.75 | -6.35% | Buy |
TMO Forecast FAQ
Is Thermo Fisher Scientific a good buy?
Yes, according to 16 Wall Street analysts, Thermo Fisher Scientific (TMO) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 13 'Buy' recommendations, accounting for 81.25% of TMO's total ratings.
What is TMO's price target?
Thermo Fisher Scientific (TMO) average price target is $646.32 with a range of $505 to $711, implying a 5.87% from its last price of $610.49. The data is based on 16 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Thermo Fisher Scientific stock go up soon?
According to Wall Street analysts' prediction for TMO stock, the company can go up by 5.87% (from the last price of $610.49 to the average price target of $646.32), up by 16.46% based on the highest stock price target, and down by -17.28% based on the lowest stock price target.
Can Thermo Fisher Scientific stock reach $900?
TMO's average twelve months analyst stock price target of $646.32 does not support the claim that Thermo Fisher Scientific can reach $900 in the near future.
What is Thermo Fisher Scientific's current price target trend?
1 Wall Street analyst forecast a $675 price target for Thermo Fisher Scientific (TMO) this month, up 10.57% from its last price of $610.49. Compared to the last 3 and 12 months, the average price target increased by 5.65% and increased by 2.99%, respectively.
What are Thermo Fisher Scientific's analysts' financial forecasts?
Thermo Fisher Scientific's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $45.48B (high $45.83B, low $44.76B), average EBITDA is $12.78B (high $12.87B, low $12.57B), average net income is $9.14B (high $9.23B, low $8.96B), average SG&A $7.81B (high $7.87B, low $7.68B), and average EPS is $23.87 (high $24.11, low $23.38). TMO's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $48.64B (high $49.01B, low $47.87B), average EBITDA is $13.66B (high $13.76B, low $13.44B), average net income is $10.03B (high $10.13B, low $9.82B), average SG&A $8.35B (high $8.41B, low $8.22B), and average EPS is $26.18 (high $26.44, low $25.64).
Did the TMO's actual financial results beat the analysts' financial forecasts?
Based on Thermo Fisher Scientific's last annual report (Dec 2023), the company's revenue was $42.86B, which missed the average analysts forecast of $42.97B by -0.27%. Apple's EBITDA was $6.86B, missing the average prediction of $11.4B by -39.84%. The company's net income was $6B, missing the average estimation of $7.59B by -20.97%. Apple's SG&A was $6.57B, missing the average forecast of $7.91B by -16.92%. Lastly, the company's EPS was $15.53, missing the average prediction of $21.71 by -28.45%. In terms of the last quarterly report (Dec 2023), Thermo Fisher Scientific's revenue was $10.89B, beating the average analysts' forecast of $10.73B by 1.43%. The company's EBITDA was $1.85B, missing the average prediction of $3.01B by -38.50%. Thermo Fisher Scientific's net income was $1.63B, missing the average estimation of $2.16B by -24.59%. The company's SG&A was $1.67B, missing the average forecast of $1.84B by -9.26%. Lastly, the company's EPS was $4.21, missing the average prediction of $5.64 by -25.41%